Alzamend Neuro Inc (ALZN)

$2.37 +0.01 (0.42%)
Market Cap 6.72M
Revenue (ttm) 0.00
Net Income (ttm) -4.51M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 133,625
Avg Vol 153,898
Day's Range N/A - N/A
Shares Out 2.90M
Stochastic %K 44%
Beta -0.30
Analysts Sell
Price Target $45.00

Company Profile

Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-pe...

Industry: Biotechnology
Sector: Healthcare
Phone: 844 722 6333
Address:
3480 Peachtree Road NE, Second Floor, Suite 103, Atlanta, United States
hiwatt
hiwatt Sep. 7 at 2:57 PM
$ALZN https://youtu.be/lWm_dyYrexc?si=5bGZjdNDBqxHP58T
0 · Reply
hiwatt
hiwatt Sep. 4 at 6:26 PM
$ALZN Not sure if anybody here saw this yesterday, Tony Dokoupil of CBS Mornings gave a personal shout out to the Lithium/ Alzheimer's study going on because of family members with the disease.
0 · Reply
hiwatt
hiwatt Sep. 2 at 6:10 PM
$ALZN Well, I guess it's better than having probes stuck in your head, lol. Tesla Dynamic Head Coil.
0 · Reply
Jdog100000000
Jdog100000000 Sep. 2 at 3:03 PM
$ALZN I remember when this was suppose to be the short of the century and then boom dark pools
0 · Reply
SimSimBola
SimSimBola Sep. 2 at 2:55 PM
$ALZN hell yea
0 · Reply
hiwatt
hiwatt Sep. 2 at 12:50 PM
$ALZN What I find most intriguing about this investment, beside the current price, is that you are not relying on some fly by night biotech raving about how their compound can possibly perform miracles. Instead, you have the Yankner's research lab at Harvard (ie-smartest people in the room) making these possible claims. These people have spent over 30 years studying Alzheimer's and over 11 years trying to prove the link between lithium and the disease theory. Problem was, the only way to prove it, was to cut open the brains of 100's of deceased subjects and measure, which is what they did. Now for the first time, they have the tools do perform those measurements on living subjects, which is happening right now. HISTORY is being made!!
0 · Reply
hiwatt
hiwatt Sep. 2 at 2:19 AM
$ALZN The holy grail of treatment for Alzheimer's disease would be a drug that not only treats underline symptoms, but also reverses the effects. When you look at the new approved drugs and the controversies surrounding them, the bar is set pretty low. Current approved Alzheimer's drugs, like lecanemab (Leqembi) and donanemab (Kisunla), target amyloid-beta protein buildup, but approval controversies stem from conflicting trial data and concerns over clinical benefits versus risks. Aducanumab (Aduhelm), initially approved with limited clinical trial evidence and serious side effects, has been discontinued by its manufacturer due to minimal uptake. The controversy highlights debates on the FDA's approval standards, the significance of amyloid plaque removal as a surrogate for disease modification, and the high costs of these treatments.
1 · Reply
wjmax
wjmax Aug. 29 at 1:35 AM
$NWBO For those who like to assign random number to the sp, here is one reason that you should be careful to put price tag. There is a company called $ALZN which is trying to develop technology using DC technology to treat Alzheimer's Dementia. Here is the trial. https://clinicaltrials.gov/study/NCT05834296 The company is trying to pulse DCs with a specific peptide (E22W) so that immune system can clean up the brain amyloid to treat Alzheimer. Can $NWBO's technology pulse DCs with this specific peptide? Absolutely! In fact, I firmly believe $NWBO can pulse DCs with all the peptides derived from the mutate gene APP that causes Alzheimer. See the attached figure? APP if highly overexpressed in three types of brain tumor can be taken care of by DCVax-L + Poly-ICLC. Remember there could be many diseases. But the answer could be just one. Having a little awe about the potential of the company will only make your get richer because you will hold your shares longer.
2 · Reply
ExecutiveEdge
ExecutiveEdge Aug. 28 at 12:59 PM
TGL is about to flip the script. Tiny float, big treasury, PR machine loaded. This is how parabolas begin. $ALZN $RCEL $LEXX $TIVC
1 · Reply
AlwaysLearning72
AlwaysLearning72 Aug. 27 at 9:29 PM
$ALZN that was a nice 10K green candle but at 2:48pm.
1 · Reply
Latest News on ALZN
Alzamend Neuro to Present at the 2025 Military Health System Research Symposium

Jul 28, 2025, 8:00 AM EDT - 6 weeks ago

Alzamend Neuro to Present at the 2025 Military Health System Research Symposium

Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs

Jul 23, 2025, 8:00 AM EDT - 6 weeks ago

Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs

Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule

Jun 16, 2025, 8:00 AM EDT - 3 months ago

Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule

Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

May 29, 2025, 8:00 AM EDT - 3 months ago

Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

May 19, 2025, 8:00 AM EDT - 4 months ago

Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

May 13, 2025, 8:00 AM EDT - 4 months ago

Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

Alzamend Neuro Announces Reverse Stock Split

May 8, 2025, 8:00 AM EDT - 4 months ago

Alzamend Neuro Announces Reverse Stock Split

Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical Trial of AL001 Study to Take Place at Massachusetts General Hospital

May 7, 2025, 8:00 AM EDT - 4 months ago

Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical Trial of AL001 Study to Take Place at Massachusetts General Hospital

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer's Disease to take Place at Massachusetts General Hospital

Mar 25, 2025, 8:00 AM EDT - 6 months ago

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer's Disease to take Place at Massachusetts General Hospital

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Major Depressive Disorder to take Place at Massachusetts General Hospital

Mar 18, 2025, 8:00 AM EDT - 6 months ago

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Major Depressive Disorder to take Place at Massachusetts General Hospital

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to take Place at Massachusetts General Hospital

Mar 11, 2025, 8:00 AM EDT - 6 months ago

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to take Place at Massachusetts General Hospital

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Bipolar Disorder to take Place at Massachusetts General Hospital

Mar 4, 2025, 8:10 AM EST - 6 months ago

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Bipolar Disorder to take Place at Massachusetts General Hospital

Alzamend Neuro Announces Initiation Date of First Phase II Clinical Trial of AL001 to take Place at Massachusetts General Hospital

Feb 25, 2025, 8:00 AM EST - 7 months ago

Alzamend Neuro Announces Initiation Date of First Phase II Clinical Trial of AL001 to take Place at Massachusetts General Hospital

Alzamend Neuro Stock Jumps After Post Traumatic Stress Disorder Study Pact: Details

Aug 19, 2024, 9:41 AM EDT - 1 year ago

Alzamend Neuro Stock Jumps After Post Traumatic Stress Disorder Study Pact: Details

Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder

Aug 19, 2024, 8:00 AM EDT - 1 year ago

Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder

ABBV

Alzamend Neuro Announces Termination of At-the-Market Equity Offering Program

May 7, 2024, 8:00 AM EDT - 1 year ago

Alzamend Neuro Announces Termination of At-the-Market Equity Offering Program

Altasciences Completes Clinical Portion of Alzamend Neuro's Phase IIa Multiple Ascending Dose Clinical Trial for Treatment of Dementia Related to Alzheimer's

Apr 18, 2023, 8:00 AM EDT - 2 years ago

Altasciences Completes Clinical Portion of Alzamend Neuro's Phase IIa Multiple Ascending Dose Clinical Trial for Treatment of Dementia Related to Alzheimer's

Ault Alliance Announces Alzamend Neuro Has Initiated Its Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer's Type

Apr 4, 2023, 6:30 AM EDT - 2 years ago

Ault Alliance Announces Alzamend Neuro Has Initiated Its Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer's Type

BitNile Holdings Contemplates Exchange Offer to Acquire Shares of Its Common Stock

Nov 28, 2022, 6:30 AM EST - 3 years ago

BitNile Holdings Contemplates Exchange Offer to Acquire Shares of Its Common Stock

In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Stephan Jackman, CEO Alzamend Neuro, Inc.

Nov 22, 2022, 8:05 AM EST - 3 years ago

In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Stephan Jackman, CEO Alzamend Neuro, Inc.

BitNile Holdings Reports Third Quarter 2022 Financial Results, Including Revenue of $100 Million for the Nine Months Ended September 30, 2022, up 124% from the Prior Year's Nine-Month Period

Nov 21, 2022, 7:27 PM EST - 3 years ago

BitNile Holdings Reports Third Quarter 2022 Financial Results, Including Revenue of $100 Million for the Nine Months Ended September 30, 2022, up 124% from the Prior Year's Nine-Month Period

BitNile Holdings Announces That Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase I/IIA Clinical Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Alzheimer's Disease

Nov 1, 2022, 6:30 AM EDT - 3 years ago

BitNile Holdings Announces That Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase I/IIA Clinical Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Alzheimer's Disease

Alzamend Neuro Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement

Sep 22, 2022, 8:00 AM EDT - 3 years ago

Alzamend Neuro Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement

Alzamend: Biotech To Watch With 2 Drugs Targeting Multi-Billion Dollar Alzheimer's Market

Dec 17, 2021, 11:59 PM EST - 4 years ago

Alzamend: Biotech To Watch With 2 Drugs Targeting Multi-Billion Dollar Alzheimer's Market

Alzamend Neuro Shares Are Trading Higher After Encourage Early-Stage Data From Alzheimer's Candidate

Dec 17, 2021, 9:54 AM EST - 4 years ago

Alzamend Neuro Shares Are Trading Higher After Encourage Early-Stage Data From Alzheimer's Candidate

See Why Alzamend Neuro Stock Is Rallying On Thursday

Sep 30, 2021, 1:45 PM EDT - 4 years ago

See Why Alzamend Neuro Stock Is Rallying On Thursday

Why Alzamend Neuro Shares Are Surging Higher Today

Sep 30, 2021, 11:54 AM EDT - 4 years ago

Why Alzamend Neuro Shares Are Surging Higher Today

Alzamend Neuro Receives Positive Pre-IND Response from FDA for AL002, a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patients' Immunological System to Combat Alzheimer's Disease

Sep 30, 2021, 10:11 AM EDT - 4 years ago

Alzamend Neuro Receives Positive Pre-IND Response from FDA for AL002, a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patients' Immunological System to Combat Alzheimer's Disease

Alzamend Neuro Announces Initiation of Phase I First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer's Disease

Sep 13, 2021, 6:30 AM EDT - 4 years ago

Alzamend Neuro Announces Initiation of Phase I First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer's Disease

Alzamend Neuro Announces Additional Investment Under Its Investigational New Drug Application for AL001 for Dementia Related to Alzheimer's Pursuant to the Securities Purchase Agreement with Digital Power Lending

Aug 4, 2021, 6:30 AM EDT - 4 years ago

Alzamend Neuro Announces Additional Investment Under Its Investigational New Drug Application for AL001 for Dementia Related to Alzheimer's Pursuant to the Securities Purchase Agreement with Digital Power Lending

Alzamend Neuro Announces Pre-IND Submission for AL002 as a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patient's Immunological System to Combat Alzheimer's

Jul 30, 2021, 6:30 AM EDT - 4 years ago

Alzamend Neuro Announces Pre-IND Submission for AL002 as a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patient's Immunological System to Combat Alzheimer's

Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase 1 Clinical Study Under Its Investigational New Drug Application for AL001 for Dementia Related to Alzheimer's Disease

Jul 28, 2021, 3:07 PM EDT - 4 years ago

Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase 1 Clinical Study Under Its Investigational New Drug Application for AL001 for Dementia Related to Alzheimer's Disease

Alzamend Neuro Stock Shoots Higher As Alzheimer's Candidate Shows Encouraging Safety Profile In Animal Models

Jul 23, 2021, 7:20 AM EDT - 4 years ago

Alzamend Neuro Stock Shoots Higher As Alzheimer's Candidate Shows Encouraging Safety Profile In Animal Models

Alzamend Neuro Receives Positive Results for AL002 in a GLP Toxicology Study Using a Transgenic Mouse Model of Alzheimer's Disease

Jul 23, 2021, 6:30 AM EDT - 4 years ago

Alzamend Neuro Receives Positive Results for AL002 in a GLP Toxicology Study Using a Transgenic Mouse Model of Alzheimer's Disease

Alzamend Neuro, Inc. to Ring Nasdaq Opening Bell Today

Jul 12, 2021, 6:00 AM EDT - 4 years ago

Alzamend Neuro, Inc. to Ring Nasdaq Opening Bell Today

Alzamend Neuro Submits IND Application For Alzheimer's-Related Dementia Candidate

Jul 1, 2021, 11:23 AM EDT - 4 years ago

Alzamend Neuro Submits IND Application For Alzheimer's-Related Dementia Candidate

Alzamend Neuro Submits IND Application for AL001 for Dementia Related to Alzheimer's Disease

Jul 1, 2021, 6:30 AM EDT - 4 years ago

Alzamend Neuro Submits IND Application for AL001 for Dementia Related to Alzheimer's Disease

Alzamend Neuro Announces Closing of Initial Public Offering and Full Exercise of Underwriter's Over-allotment Option for Gross Proceeds of $14.4 Million

Jun 17, 2021, 4:30 PM EDT - 4 years ago

Alzamend Neuro Announces Closing of Initial Public Offering and Full Exercise of Underwriter's Over-allotment Option for Gross Proceeds of $14.4 Million

Ault Global Holdings Announces Alzamend Neuro Pricing of Initial Public Offering

Jun 16, 2021, 6:30 AM EDT - 4 years ago

Ault Global Holdings Announces Alzamend Neuro Pricing of Initial Public Offering

Alzamend Neuro Announces Pricing of Initial Public Offering

Jun 14, 2021, 5:49 PM EDT - 4 years ago

Alzamend Neuro Announces Pricing of Initial Public Offering

hiwatt
hiwatt Sep. 7 at 2:57 PM
$ALZN https://youtu.be/lWm_dyYrexc?si=5bGZjdNDBqxHP58T
0 · Reply
hiwatt
hiwatt Sep. 4 at 6:26 PM
$ALZN Not sure if anybody here saw this yesterday, Tony Dokoupil of CBS Mornings gave a personal shout out to the Lithium/ Alzheimer's study going on because of family members with the disease.
0 · Reply
hiwatt
hiwatt Sep. 2 at 6:10 PM
$ALZN Well, I guess it's better than having probes stuck in your head, lol. Tesla Dynamic Head Coil.
0 · Reply
Jdog100000000
Jdog100000000 Sep. 2 at 3:03 PM
$ALZN I remember when this was suppose to be the short of the century and then boom dark pools
0 · Reply
SimSimBola
SimSimBola Sep. 2 at 2:55 PM
$ALZN hell yea
0 · Reply
hiwatt
hiwatt Sep. 2 at 12:50 PM
$ALZN What I find most intriguing about this investment, beside the current price, is that you are not relying on some fly by night biotech raving about how their compound can possibly perform miracles. Instead, you have the Yankner's research lab at Harvard (ie-smartest people in the room) making these possible claims. These people have spent over 30 years studying Alzheimer's and over 11 years trying to prove the link between lithium and the disease theory. Problem was, the only way to prove it, was to cut open the brains of 100's of deceased subjects and measure, which is what they did. Now for the first time, they have the tools do perform those measurements on living subjects, which is happening right now. HISTORY is being made!!
0 · Reply
hiwatt
hiwatt Sep. 2 at 2:19 AM
$ALZN The holy grail of treatment for Alzheimer's disease would be a drug that not only treats underline symptoms, but also reverses the effects. When you look at the new approved drugs and the controversies surrounding them, the bar is set pretty low. Current approved Alzheimer's drugs, like lecanemab (Leqembi) and donanemab (Kisunla), target amyloid-beta protein buildup, but approval controversies stem from conflicting trial data and concerns over clinical benefits versus risks. Aducanumab (Aduhelm), initially approved with limited clinical trial evidence and serious side effects, has been discontinued by its manufacturer due to minimal uptake. The controversy highlights debates on the FDA's approval standards, the significance of amyloid plaque removal as a surrogate for disease modification, and the high costs of these treatments.
1 · Reply
wjmax
wjmax Aug. 29 at 1:35 AM
$NWBO For those who like to assign random number to the sp, here is one reason that you should be careful to put price tag. There is a company called $ALZN which is trying to develop technology using DC technology to treat Alzheimer's Dementia. Here is the trial. https://clinicaltrials.gov/study/NCT05834296 The company is trying to pulse DCs with a specific peptide (E22W) so that immune system can clean up the brain amyloid to treat Alzheimer. Can $NWBO's technology pulse DCs with this specific peptide? Absolutely! In fact, I firmly believe $NWBO can pulse DCs with all the peptides derived from the mutate gene APP that causes Alzheimer. See the attached figure? APP if highly overexpressed in three types of brain tumor can be taken care of by DCVax-L + Poly-ICLC. Remember there could be many diseases. But the answer could be just one. Having a little awe about the potential of the company will only make your get richer because you will hold your shares longer.
2 · Reply
ExecutiveEdge
ExecutiveEdge Aug. 28 at 12:59 PM
TGL is about to flip the script. Tiny float, big treasury, PR machine loaded. This is how parabolas begin. $ALZN $RCEL $LEXX $TIVC
1 · Reply
AlwaysLearning72
AlwaysLearning72 Aug. 27 at 9:29 PM
$ALZN that was a nice 10K green candle but at 2:48pm.
1 · Reply
ItTakesItAll
ItTakesItAll Aug. 26 at 8:43 AM
$ALZN $BSLK $ONCO $OPAD $STKH since this post, 2 massive gains, one going now, 2 opportunities still to come.
0 · Reply
avocadro
avocadro Aug. 23 at 2:01 PM
$ALZN Jabba will get your money! Look at DPW and bunch of his other scams.
1 · Reply
ScalpChaser
ScalpChaser Aug. 23 at 5:25 AM
$ALZN Alzamend Neuro is a preclinical biotech developing Alzheimer's treatments with very high risk and funding needs
1 · Reply
Asrm088
Asrm088 Aug. 23 at 12:08 AM
$ALZN when $6.5💰💵
1 · Reply
LesterDiamond99
LesterDiamond99 Aug. 22 at 3:43 PM
$ALZN Who’s the next price target from? My neighbor? 🤣
1 · Reply
Clifden
Clifden Aug. 22 at 1:39 PM
$ALZN Maybe they can get a price target 🎯 from Esousa also 🥷🗑🪤
0 · Reply
SimSimBola
SimSimBola Aug. 21 at 9:54 PM
$ALZN maybe so...but this will rise regardless. it's coming
0 · Reply
NJMarty
NJMarty Aug. 21 at 8:37 PM
$ALZN Ascendiant Capital's analyst Edward Woo has recently maintained a "Buy" rating for Alzamend Neuro (ALZN, Financial). Despite the consistent rating, there is a significant adjustment in the price target for the company's stock. The price target for Alzamend Neuro (ALZN, Financial) has been lowered from $180.00 to $45.00. This adjustment represents a 75% reduction in the previously anticipated value, as per the data provided by Ascendiant Capital. This notable price target change reflects a more conservative outlook while still retaining confidence in the stock's potential, as indicated by the maintained "Buy" rating. Investors are advised to take note of this updated guidance on Alzamend Neuro (ALZN, Financial) as they assess their investment strategies.
0 · Reply
Scrood_the_Pooch
Scrood_the_Pooch Aug. 21 at 8:05 PM
$ALZN Ascendiant is their dilution company. Go back and look, they have ALWAYS had pie-in-the-sky price targets. Thousands of dollars per share ago. Total BS.
0 · Reply
SimSimBola
SimSimBola Aug. 21 at 3:25 PM
$ALZN they off by 15. correct price target is $60😎
0 · Reply
vzlano25
vzlano25 Aug. 21 at 1:39 PM
$ALZN TOTAL SCAM!!
0 · Reply
AlwaysLearning72
AlwaysLearning72 Aug. 21 at 10:42 AM
$ALZN wow! $45 price target from Ascendiant capital this morning
0 · Reply